Please use this identifier to cite or link to this item: https://doi.org/10.1126/scitranslmed.3002296
DC FieldValue
dc.titleTargeting intracellular oncoproteins with antibody therapy or vaccination
dc.contributor.authorGuo, K.
dc.contributor.authorLi, J.
dc.contributor.authorTang, J.P.
dc.contributor.authorTan, C.P.B.
dc.contributor.authorHong, C.W.
dc.contributor.authorAl-Aidaroos, A.Q.O.
dc.contributor.authorVarghese, L.
dc.contributor.authorHuang, C.
dc.contributor.authorZeng, Q.
dc.date.accessioned2014-12-12T07:13:55Z
dc.date.available2014-12-12T07:13:55Z
dc.date.issued2011-09-07
dc.identifier.citationGuo, K., Li, J., Tang, J.P., Tan, C.P.B., Hong, C.W., Al-Aidaroos, A.Q.O., Varghese, L., Huang, C., Zeng, Q. (2011-09-07). Targeting intracellular oncoproteins with antibody therapy or vaccination. Science Translational Medicine 3 (99) : -. ScholarBank@NUS Repository. https://doi.org/10.1126/scitranslmed.3002296
dc.identifier.issn19466234
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/115312
dc.description.abstractAntibody-based therapies have better specificity and thus improved efficacy over standard chemotherapy regimens, which result in extended survival and improved quality of life for cancer patients. Because antibodies are viewed as too large to access intracellular locations, antibody therapy has traditionally targeted extracellular or secreted proteins expressed by cancer cells. However, many oncogenic proteins are found within the cell (such as intracellular phosphatases/kinases and transcription factors) and have therefore not been pursued for antibody therapies. Here, we explored the possibility of antibody therapy or vaccination against intracellular proteins. As proofs of concept, we selected three representative intracellular proteins as immunogens for tumor vaccine studies: PRL-3 (phosphatase of regenerating liver 3), a cancer-associated phosphatase; EGFP (enhanced green fluorescent protein), a general reporter; and mT (polyomavirus middle T), the polyomavirus middle T oncoprotein. A variety of tumors that expressed these intracellular proteins were clearly inhibited by their respective exogenous antibodies or by antigen-induced host antibodies (vaccination). These anticancer activities were reproducibly observed in hundreds of C57BL/6 tumor-bearing mice and MMTV-PymT transgenic breast tumor mice. Our in vivo data suggest that immunotherapies can target not only extracellular but also intracellular oncoproteins.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1126/scitranslmed.3002296
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentINSTITUTE OF MOLECULAR & CELL BIOLOGY
dc.description.doi10.1126/scitranslmed.3002296
dc.description.sourcetitleScience Translational Medicine
dc.description.volume3
dc.description.issue99
dc.description.page-
dc.identifier.isiut000294663900004
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

71
checked on May 18, 2022

WEB OF SCIENCETM
Citations

67
checked on May 18, 2022

Page view(s)

167
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.